

Biotinylated Cynomolgus ALPI Protein; His-Avi Tag

Product Information

| Product Name | Biotinylated Cynomolgus ALPI Protein; His-Avi Tag |
|-----------------|---|
| Storage temp. | Store at \leq -70°C, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Catalog# / Size | GM-85155RP-25 / 25 μg GM-85155RP-200 / 200 μg |

Protein Information


| Alternative Names | IAP |
|--------------------|--|
| Source | Biotinylated Cynomolgus ALPI Protein; His-Avi Tag (GM-85155RP) is |
| | expressed from human 293 cells (HEK-293). It contains AA Ile20-Asp502 |
| | (Accession # A0A2K5VFX3). |
| | This protein carries a His-Avi tag at the C-terminus. |
| Purity | > 95% as determined by SDS-PAGE |
| Endotoxin | $< 1 \text{ EU/}\mu g$, determined by LAL gel clotting assay |
| Predicted Mol Mass | 56.9 KDa |
| Formulation | Supplied as a 0.2 µm filtered solution of PBS, pH7.4. |
| Description | Intestinal alkaline phosphatase (ALPI) is an enzyme primarily encoded by the |
| | ALPI gene in the human body. This enzyme is mainly present in the small |
| | intestine and the liver, and can also be found in other tissues, although in smaller |
| | amounts. The main function of intestinal alkaline phosphatase in the small |
| | intestine is to assist in the digestion and absorption of phosphates and fats from |
| | food. Additionally, it is used as one of the clinical diagnostic markers for detecting |
| | intestinal diseases or bone disorders. Research on ALPI in human diseases also |
| | suggests that it may play a role in certain intestinal diseases and inflammatory |
| | processes. IAP is essential for lipids absorption and is involved in reducing |
| | inflammation. IAP suppresses inflammation, particularly by modifying the gut |
| | microflora and dephosphorylating LPS. Any alteration in IAP expression and |
| | activity increases the vulnerability to inflammation. Inflammatory bowel disease |
| | (IBD) is an indication of a condition where the patient's endogenous IAP |
| | |

(IBD) is an indication of a condition where the patient's endogenous IAP production and activity are reduced. Exogenous IAP injection may be a good option for treating IBD and other disorders caused by the disruption of gut microbiota.

Version:3.3 Revision Date:25/12/2023




SDS-PAGE



On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Biotinylated Cynomolgus ALPI Protein; His-Avi Tag, ELISA

Bioactivity-ELISA



Biotinylated Cynomolgus ALPI Protein; His-Avi Tag (Catalog # GM-85155RP) was immobilized at 1 µg/ml (100 µL/well) on streptavidin precoated. Increasing concentrations of Anti-His mIgG2a Antibody (Catalog # GM-59493AB) were added.